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ABSTRACT
Introduction: The aim of this study was to
observe the effect of stress caused by
neuropathic pain on serum cortisol
concentration and expression of 11b-
hydroxysteroid dehydrogenase type I enzyme
(11bHSD1) in spinal cord and dorsal root
ganglions (DRG) and investigate the role and
mechanism of curcumin in the neuropathic
pain of stressful rats. Neuropathic pain is a
prevalent disease that greatly impairs the
patients’ quality of life. A lack of the
understanding of its etiology, inadequate
relief, development of tolerance and potential
toxicity of classical antinociceptives warrant the
investigation of the newer agents to relieve this
pain. The aim of the present study was to
explore the antinociceptive effect of curcumin
and its effect on expression of 11b-
hydroxysteroid dehydrogenase type I enzyme
(11bHSD1) in spinal dorsal horn and DRG in
chronic constriction injury (CCI) mode of
neuropathic pain of rats.
Methods: Seventy-two male Sprague-Dawley
rats were randomized into four groups with 18
rats in each: sham operation group (Sham),
chronic constrictive injury group (CCI), solvent
contrast group (SC), and curcumin-treated
group (Cur100). Curcumin, 100 mg/kg/day
intraperitoneal, was given for 14 days starting
from the first day after operation in the Cur100
group. Paw thermal withdrawal latency (PTWL)
and paw mechanical withdrawal threshold
(PMWT) of rats were measured 2 days pre-
operative, and 1, 3, 5, 7, 10, and 14 days post-
operative. The animals were deeply
anesthetized and blood was taken from the
Electronic supplementary material The online
version of this article (doi:10.1007/s40122-014-0024-4)
contains supplementary material, which is available to
authorized users.
Y. X. Di (&)
The Anesthesiology Department of YiChang Central
People’s Hospital, The First College of Clinical
Medical Science, China Three Gorges University,
Yichang, China
e-mail: yuxiangdidream@163.com
C. Hong  L. Jun  L. Qinquan
Department of Anesthesiology, Second Affiliated
Hospital, Wenzhou Medical College, Pain Institute
of Wenzhou Medical College, Wenzhou, China
e-mail: caohongxz@yahoo.com.cn
G. Renshan
Population Council, The Rockefeller University,
New York, NY, USA
Pain Ther (2014) 3:59–69
DOI 10.1007/s40122-014-0024-4
heart, the lumbar segment (L4, 5) of the spinal
cord and DRG were dissected out and
homogenized. The change of cortisol was
measured by enzyme-linked immunosorbent
assay and the change of 11bHSD1 expression
was determined by immunochemistry and
Western blot.
Results: Compared with sham group, PTWL
and PMWT significantly decrease after
operation in the CCI group; serum cortisol
concentration was significantly increased and
the expression of 11bHSD1 was significantly
increased in the CCI group. Comparing with
CCI group, the PMWT and PTWL were
increased and the serum cortisol concentration
was decreased and the expression of 11bHSD1
was inhibited in Cur100 group.
Conclusion: Stress caused by neuropathic pain
triggers release of cortisol to the blood and
expression of 11bHSD1 would increase at the
same time. Curcumin could alleviate thermal
and mechanical hyperalgesia induced by CCI
and inhibit the serum cortisol concentration
and expression of 11bHSD1 in the spinal cord
and DRG.
Keywords: 11bHSD1; Cortisol; Curcumin;
Neuropathic pain; Pain; Sprague-Dawley rat;
Stress
INTRODUCTION
Neuropathic pain can be considered a form of
chronic stress, and neuropathic pain patients
often have disturbance of the hypothalamic–
pituitary–adrenal (HPA) axis, including
abnormal cortisol levels [1]. In addition, the
11b-hydroxysteroid dehydrogenase type I
enzyme (11bHSD1) is the key enzyme that
converts cortisone to cortisol in humans, and
11-dehydrocorticosterone to corticosterone in
rodents [2]. Glucocorticoid that includes
cortisol and corticosterone has its effect
through glucocorticoid receptors (GRs). A
previous study has shown that central GRs
play an important role in development and
maintenance of neuropathic pain by
participating and regulating the expression
and function of N-methyl-D-aspartate receptor
[3]. The authors and other previous studies have
shown that curcumin can attenuate thermal
and mechanical hyperalgesia in a diabetic
mouse model of neuropathic pain [4, 5].
The current study employs a rodent
neuropathic pain model [chronic constriction
injury (CCI) of the sciatic nerve] to assess the
effect of chronic stress on the releasing of
cortisol in the serum and expression of
11bHSD1 in spinal dorsal horn and dorsal root
ganglion (DRG). In addition, we explore the
effect of curcumin on thermal hyperalgesia and
mechanical allodynia and its effect on
expression of 11bHSD1 in spinal dorsal horn
and DRG.
METHODS
Procedure for Chronic Constriction Injury
Chronic constriction injury rats were produced
by loosely ligating a common sciatic nerve
according to the method of Bennett and Xie
[6]. Rats were anesthetized with sodium
pentobarbital (40 mg/kg, intraperitoneal). The
common sciatic nerve was exposed at the level
of the middle of the thigh by blunt dissection
through biceps femoris, 4 ligatures (4-0 chromic
gut suture) were tied loosely around it with
about 1 mm spacing. The incision was closed in
layers. The success of the modeling was
confirmed by detecting thermal and
mechanical hyperalgesia.
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Experimental Animal and Grouping
Male Sprague-Dawley rats were obtained from
the Animal Center of Wenzhou Medical College
(Zhejiang, China) and were housed in groups of
2–4 in 40 9 60 9 30 cm plastic cages with soft
bedding under a 12/12 h day/night cycle; water
and food pellets were available ad libitum.
Experiments were conducted with the
approval of the Animal Care Committee of
Wenzhou Medical College and according to the
guidelines for investigations of experimental
pain in animals published by the International
Association for the Study of Pain [7]. Sham and
CCI rats were randomly selected and divided in
four groups with six animals in each. The first
group consisted of sham rats, the second group
was the CCI control rats, the third group was
the solvent control (SC) group, and the fourth
group consisted of the CCI rats (Cur100) which
were treated with curcumin 100 mg/kg/day by
peritoneal injection for 14 days starting from
the first day after the CCI operation. The sham
and solvent control groups received the vehicle
of curcumin [dimethyl sulfoxide (DMSO)], and
the CCI group was treated with nothing.
Behavioral Studies
Paw thermal withdrawal latency (PTWL) and
paw withdrawal mechanical threshold (PWMT)
of rats were measured 2 days pre-operative and
1, 3, 5, 7, 10, and days 14 post-operative.
Mechanical allodynia was assessed by use of
von Frey filaments. Rats were placed in
individual plastic boxes (20 9 25 9 15 cm) on a
metal mesh floor and allowed to acclimatize for
30 min. The filaments were presented, in
ascending order of strength, perpendicular to
the plantar surface with sufficient force to cause
slight bending against the paw and held for
6–8 s. Brisk withdrawal or paw flinching were
considered as positive responses. The PWMT
was determined by sequentially increasing and
decreasing the stimulus strength (the ‘‘up-and-
down’’ method) [8], and the data were analyzed
using the nonparametric method of Dixon, as
described by Chaplan et al. [8].
Thermal hyperalgesia was assessed with the
PTWL to radiant heat according to the protocol
of Hargreaves et al. [9]. Rats were placed in clear
plastic cages on an elevated glass plate and
allowed to acclimatize for 30 min before testing.
A radiant thermal stimulator was focused onto
the plantar surface of the hind paw through the
glass plate. The nociceptive endpoints in the
radiant heat test were the characteristic lifting
or licking of the hind paw, and the time to the
endpoint was considered the PTWL. To avoid
tissue damage, a cut-off time of 30 s was used
[10]. There were five trials per rat with 5-min
intervals between trials. The mean PTWL was
obtained from the final three stimuli [11].
Enzyme-Linked Immunosorbent Assay
Enzyme-linked immunosorbent assay (ELISA)
was used to detect serum cortisol concentration.
On 3, 7, and 14 days post-operative, the blood
was taken from the heart of the rats with
pentobarbital sodium (40 mg/kg) and
centrifuged to get supernatant between 10
a.m. and noon to minimize the variation of
the plasma cortisol level. The cortisol ELISA-kit
was purchased from Boyun Biotechnology
Company (Shanghai, China). The standard
curve was generated using the reference
standard set supplied in the kit. The samples
were measured according to the instructions
accompanying the kit. The results were read
using a microplate reader (Elx-800, Bio-Tek
instruments, Inc, Winooski, VT, USA) at
wavelengths of 450 nm. The plasma cortisol
concentration was calculated based on the
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standard curve and presented in nanograms per
milliliter.
Immunohistochemical Staining
Immunohistochemistry was used to detect
11bHSD1 immunoreactivities in spinal dorsal
horn and DRG. On 3, 7, and 14 days post-
operative, rats anesthetized with pentobarbital
sodium (40 mg/kg, intraperitoneal) were
perfused through the ascending aorta with
0.9% NaCl, followed by freshly prepared 4%
paraformaldehyde in 0.1 M phosphate-buffered
saline (PBS; pH 7.4). The lumbosacral spinal
cords and L4–5 DRG which were ipsilateral to
the operation were carefully dissected out,
embedded in paraffin. Five-micron-thick cross-
sections of paraffin-embedded tissue were cut
and mounted on Vectabond adhesive-coated
slides. Sections were dewaxed in xylene and
rehydrated in ethanol, then washed in PBS,
sections were incubated with the primary
antibody (11bHSD1, 1:500, Experimental
Center of Rockefeller University, USA) dilution
at 4 C for 24 h. Sections were washed twice
with PBS and incubated in goat anti-rabbit
serum (1:200) (Chemicon Group, USA) for 1 h.
This step was followed by three washes in PBS
and staining using the ABC kit. The DAB
chromogenic reaction was monitored carefully
for about 5 min and PBS was used to stop the
reaction in time.
Western Blot Analysis
Western blot was used to detect 11bHSD1
expression in spinal dorsal horn and DRG.
Rats were rapidly (\1 min) killed through
decapitation after being anesthetized with
pentobarbital (50 mg/kg, intraperitoneal). The
lumbosacral spinal cords and L4,5 DRG which
were ipsilateral to the operation were carefully
dissected out and homogenized in SDS sample
buffer containing a mixture of proteinase
inhibitors. The lumbar segments and
corresponding DRG were harvested because
CCI has the major impact at these spinal
segments. Protein samples and the loading b-
actin were separated via 10% gel electrophoresis
and electroblotted onto polyvinylidene fluoride
(PVDF) membranes. Nonspecific binding sites
were blocked by incubating PVDF membranes
for 1 h in PBS containing 5% low-fat dry milk.
Membranes were incubated overnight at 4 C
with primary antibodies (11bHSD1, 1:3,000;
Rockefeller University, New York, NY, USA)
and for 1 h at room temperature with anti-
rabbit secondary antibodies (1:1,000; Chemicon
Group, New York, USA). Blots were developed
using an enhanced chemiluminescence
detection system (ECL; Amersham Pharmacia
Biotech, Piscataway, NJ, USA) according to the
manufacture’s instruction. The Western
analysis was made in triplicates. The density of
specific bands was measured with a computer-
assisted imaging analysis system and
normalized against loading controls.
Differences were compared using repeated
measures one-way analysis of variance
(ANOVA) followed by post hoc Newman–Keuls
tests.
Statistical Analysis
Results were expressed as the mean ± SE of at
least three separate experiments and analyzed
using the SPSS16.0 statistical program (SAS
Institute Inc, Cary, North Carolina). The
behavior data were analyzed by using repeated
measures ANOVA followed by the Fisher’s least
significant difference (LSD) test. Differences
with P values of \0.05 were considered
significant.
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RESULTS
The Change of PWMT and PTWL Baseline
in Each Group
There was no statistical difference of PWMT and
PTWL baseline among the groups. After
operation, the sham group exhibited no
significant difference of PWMT and PTWL at
different time points. PWMT and PTWL of CCI
group began to decline from day 1 after the
operation and reached the minimum value
(52.6% of basal value) on day 10, then
recovered slowly, but it was still lower than the
basic value on day 14. The CCI group exhibited a
significant decrease of PWMT and PTWL
compared with sham group (P\0.01) (Fig. 1).
There was no difference between CCI group and
SC group (P[0.05) (Fig. 1).
Effect of Chronic Curcumin Treatment
on Nociceptive Threshold of PWMT
and PTWL
When curcumin treatment started from the day
1 after the operation for 14 days, no statistic
difference of PWMT and PTwL was exhibited
between the Cur100 group and CCI group on 1,
3, and 5 days after operation. However, PWMT
and PTWL of the Cur100 group were improved
as compared to CCI group on day 7 (P\0.05)
(Fig. 1). On day 10 after the operation, PWMT
and PTWL of Cur100 was improved compared
to the CCI group (P\0.05) (Fig. 1). On day 14,
PWMT and PTWL of Cur100 group was
significantly improved as compared to CCI
group and SC group (P\0.05) (Figs. 1, 2).
The Change of Serum Cortisol
Concentration in Each Group
After operation, the sham group exhibited no
significant difference of serum cortisol
concentration at different time points
(P[0.05); compared with sham group, serum
cortisol concentration of CCI and SC groups
increased significantly on day 3 (P\0.01),
reached a peak point on day 7 (36.32 ± 15.71)
and on day 14 it was still higher than sham
group (P\0.05). Compared with CCI group,
Fig. 1 Effect of curcumin treatment on the paw with-
drawal thermal latency in CCI rats (n = 6 rats/group;
mean ± SD; **P\0.01 vs. sham group; #P\0.05 vs. CCI
group; 4P\0.05 vs. SC group). sham operation group
(Sham), chronic constrictive injury group (CCI), solvent
contrast group (SC), and curcumin-treated group (Cur100)
Fig. 2 Effect of curcumin treatment on the paw with-
drawal mechanical threshold with von Frey ﬁlaments in
CCI rats (n = 6 rats/group; mean ± SD; **P\0.01 vs.
sham group; #P\0.05 vs. CCI group; 4P\0.05 vs. SC
group). Sham operation group (Sham), chronic constric-
tive injury group (CCI), solvent contrast group (SC), and
curcumin-treated group (Cur100)
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serum cortisol concentration of Cur100 group
declined (P\0.05) (Fig. 3).
Effect of Neuropathic Pain of CCI Mode
on Expression of 11bHSD1 in Spinal Dorsal
Horn and DRG
The effect of neuropathic pain on 11bHSD1
expression was determined in the superficial
dorsal horn laminae I–III of the lumbar
enlargement and DRG, which are areas that
are involved in the transmission of nociceptive
inputs and sympathetic outflow. In the current
study, constitutive 11bHSD1 expression was
weak to absent in the sham group. In
association with the development of
neuropathic pain in CCI group, there was a
time-dependent upregulation of 11bHSD1
Fig. 3 Effect of curcumin on serum cortisol concentration
after CCI operation (mean ± SD, n = 6). **P\0.01 vs.
sham group; #P\0.05 vs. CCI group. Sham operation
group (Sham), chronic constrictive injury group (CCI),
solvent contrast group (SC), and curcumin-treated group
(Cur100)
Fig. 4 Effect of curcumin on the expression of 11bHSD1
in dorsal root ganglion after CCI operation (mean ± SD,
n = 6). **P\0.01 vs. sham group; #P\0.05 vs. CCI
group. Sham operation group (Sham), 11b-hydroxysteroid
dehydrogenase type I enzyme (11bHSD1), chronic con-
strictive injury group (CCI), solvent contrast group (SC),
and curcumin-treated group (Cur100)
Fig. 5 Effect of curcumin on the expression of 11bHSD1
in spinal dorsal horn after CCI operation (mean ± SD,
n = 6). **P\0.01 vs. sham group; #P\0.05 vs. CCI
group. 11b-hydroxysteroid dehydrogenase type I enzyme
(11bHSD1), sham operation group (Sham), chronic
constrictive injury group (CCI), solvent contrast group
(SC), and curcumin-treated group (Cur100)
Fig. 6 Effect of curcumin on the expression of 11bHSD1
in spinal dorsal horn after CCI operation (mean ± SD,
n = 6). **P\0.01 vs. Sham group; #P\0.05 vs. CCI
group. Sham operation group (Sham), 11b-hydroxysteroid
dehydrogenase type I enzyme (11bHSD1), chronic con-
strictive injury group (CCI), solvent contrast group (SC),
and curcumin-treated group (Cur100)
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within the superficial dorsal horn laminae I–III
of the lumbar enlargement and DRG compared
with sham group (P\0.01), as revealed by
immunohistochemical staining and Western
blot. Spinal 11bHSD1 expression began to
increase on day 3 and continue to rise on day
7 and day 14 of the experimental period as
compared with the sham group (P\0.01)
(Figs. 4, 5, 6, 7, 8, 9, 10, 11).
Effect of Chronic Curcumin Treatment
on Expression of 11bHSD1 in Spinal Dorsal
Horn and DRG
The result from this experiment showed that
upregulation of 11bHSD1 expression within the
Fig. 7 Effect of curcumin on the expression of 11bHSD1
in dorsal root ganglion after CCI operation (mean ± SD,
n = 6). **P\0.01 vs. Sham group; #P\0.05 vs. CCI
group. Sham operation group (Sham), 11b-hydroxysteroid
dehydrogenase type I enzyme (11bHSD1), chronic con-
strictive injury group (CCI), solvent contrast group (SC),
and curcumin-treated group (Cur100)
Fig. 8 Effect of curcumin 100 mg/kg intraperitoneal on
expression of 11bHSD1 in spinal dorsal horn on day 7 after
CCI operation. From the left to the right Sham group, CCI
group, SC group, Cur100 group (9400). Sham operation
group (Sham), 11b-hydroxysteroid dehydrogenase type I
enzyme (11bHSD1), chronic constrictive injury group
(CCI), solvent contrast group (SC), and curcumin-treated
group (Cur100)
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spinal dorsal horn and DRG was blocked by the
administration of curcumin on days 3, 7, and 14
by both immunohistochemical staining and
Western blot in the Cur100 group compared
with the CCI group (P\0.05) (Figs. 4,5, 6, 7, 8,
9, 10, 11).
DISCUSSION
The present study demonstrates that: (1) the
CCI group exhibited a significant decrease of
PWMT and PTWL compared with sham group,
this is in line with observation of Bennett and
Xie [6]; (2) serum cortisol concentration was
significantly increased and the expression of
11bHSD1 was significantly increased in the CCI
group; (3) chronic treatment with curcumin
significantly attenuated mechanical and
thermal hyperplasia; (4) curcumin reduced the
serum cortisol concentration and inhibited the
expression of neuronal 11bHSD1 within the
superficial spinal dorsal horn and DRG that
were ipsilateral to the operation.
These findings indicate that curcumin
prevents neuropathic pain through reducing
the expression of neuronal 11bHSD1 within the
superficial spinal dorsal horn and DRG. 11b-
Hydroxysteroid dehydrogenases (11bHSDs) are
the key enzymes that catalyze the
interconversion of glucocorticoids
(corticosterone in rodents) and their 11-keto-
metabolites (11-dehydrocorticosterone).
11bHSD1 type 1 acts predominantly as a
reductase in vivo, catalyzing the regeneration
Fig. 9 Effect of curcumin 100 mg/kg intraperitoneal on
expression of 11bHSD1 in DRG on day 7 after CCI
operation. From the left to the right Sham group, CCI
group, SC group, Cur100 group (9200). Sham operation
group (Sham), 11b-hydroxysteroid dehydrogenase type I
enzyme (11bHSD1), chronic constrictive injury group
(CCI), solvent contrast group (SC), and curcumin-treated
group (Cur100)
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of active glucocorticoids and thereby promoting
activation of GRs in target tissues [2]. The
analysis of cloned gene sequence has
discovered that CTGATACAG sequences are
located in the promoter of 11bHSD1 gene-
197–190 base-pairs; it strongly prompts that
glucocorticoid is regulated by promoter of
11bHSD1 gene. It is also reported that
glucocorticoid has induced effects on 11bHSD1
[12].
Fig. 10 Semi-quantitative value of 11bHSD1 expression
within the spinal dorsal horn after CCI on 3, 7, and
14 days post-operative. From right to left Sham group, SC
group, CCI group, Cur100 group. Sham operation group
(Sham), 11b-hydroxysteroid dehydrogenase type I enzyme
(11bHSD1), chronic constrictive injury group (CCI),
solvent contrast group (SC), and curcumin-treated group
(Cur100)
Fig. 11 Semi-quantitative value of 11bHSD1 expression
within the spinal dorsal horn after CCI on 3, 7, and
14 days post-operative. From right to left Sham group, SC
group, CCI group, Cur100 group. Sham operation group
(Sham), 11b-hydroxysteroid dehydrogenase type I enzyme
(11bHSD1), chronic constrictive injury group (CCI),
solvent contrast group (SC), and curcumin-treated group
(Cur100)
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Neuropathic pain is a form of chronic stress
and the HPA axis is activated; the
hypothalamus secretes corticotrophin-releasing
hormone (CRH) under the influence of
serotonin from the amygdale. Subsequently,
CRH stimulates the pituitary to release
adrenocorticotropic hormone, which results in
the production of glucocorticoid (cortisol) in
the adrenal cortex. It has demonstrated that
altered GR expression in limbic brain regions,
adrenal gland hypertrophy in response to
enhanced adrenocortical stimulation, chronic
pain patients often have disturbances of the
HPA axis and limbic system (e.g., hippocampus
and amygdale) [1]; in addition, clinical studies
suggest that chronic pain-induced dysfunction
of the HPA axis may be involved in reduced
sensitivity of GRs to glucocorticoid negative
feedback [13].
Peripheral GRs play a significant role in the
anti-inflammatory effects of glucocorticoids;
however, GRs have also been located in spinal
cord dorsal horn neurons. It has been found
that activation of neuron GRs contributes to
central changes related to neuronal injury [14].
In a previous study, the rats exposure to acute
stress immediately prior to nerve injury
increased neuropathic pain and rats treated
with corticosterone exhibited increased
allodynia compared to rats treated with the
vehicle [15]. Another study has found that
adrenalectomized CCI rats failed to develop
neuropathic pain behaviors; however, the
development of neuropathic pain behaviors
after CCI is restored in adrenalectomy ADL
rats when treated with dexamethasone [16].
Glucocorticoid action in cells is mediated by a
specific receptor protein, the GR; the GR level
increases in the CNS and it plays important role
in the neuropathic pain. Inhibition of GRs with
the GR antagonist RU38483 attenuates the
development of neuropathic pain [16].
The present study has shown that stress
caused by neuropathic pain triggers release of
cortisol to the blood and expression of 11bHSD1
would increase at the same time. Curcumin
could alleviate thermal and mechanical
hyperalgesia induced by CCI and inhibit the
serum cortisol concentration and expression of
11bHSD1 in spinal cord and DRG. Upregulation
of 11bHSDs will activate glucocorticoid and
promote activation of GRs. Glucocorticoid and
GRs have been proven to be the key element in
the neuropathic pain [3, 16]. It demonstrates
that that curcumin’s attenuation of
neuropathic pain is related to inhibition of the
expression of 11bHSD1 in spinal dorsal horn
and DRG. Curcumin has been used in Asian
medicine for more than 4,000 years for the
treatment of wounds, tumors, and
inflammatory conditions. It is a very potent
drug as a therapeutic or preventive agent for
several major human diseases. Curcumin has
been proven to inhibit p-Jun N-terminal kinase
p-JNK and c-jun [5] in neuropathic pain model
and inhibit tumor necrosis factor TNF-a and
nitrogen monoxide (NO) in a diabetic mouse
model of neuropathic pain [4].
CONCLUSION
Based on the present preliminary results, we
conclude that stress caused by neuropathic pain
triggers release of cortisol to the blood and
expression of 11bHSD1 would increase in the
spinal cord and DRG at the same time.
Curcumin could alleviate thermal and
mechanical hyperalgesia induced by CCI and
inhibit the serum cortisol concentration and
expression of 11bHSD1 in spinal cord and DRG.
Further studies are warranted to explore the
exact mechanism of curcumin’s antinociceptive
effect.
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